Evolus reported break-even to slight profitability in Q2 2026, extending its streak to three consecutive profitable quarters—a meaningful inflection for the Jeuveau manufacturer. Revenue reached $84.08M, up 21% year-over-year, topping analyst expectations. The company raised full-year 2026 guidance on the back of sustained demand for its neuromodulator and growing market share in the toxin category.
Business & M&A
Evolus Posts Third Straight Profitable Quarter
Jeuveau maker hits profitability milestone as revenue growth accelerates and management raises full-year guidance.
1-YEAR MOVE
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
Revenue up 21% YoY; company raises full-year guidance after third straight profitable quarter.
For practice owners, the significance lies in Evolus's stabilizing margin profile and the signal it sends about Jeuveau's competitive positioning. A profitable, growing toxin player with raised guidance typically means more aggressive rebate and loyalty programs—and potentially tighter pricing discipline across the category. Watch for Evolus Rewards program adjustments and any shifts in per-unit economics on your next order.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.